CAMP4 Therapeutics (NASDAQ:CAMP – Get Free Report) and Genelux (NASDAQ:GNLX – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations and dividends.
Insider & Institutional Ownership
37.3% of Genelux shares are held by institutional investors. 21.7% of CAMP4 Therapeutics shares are held by company insiders. Comparatively, 7.5% of Genelux shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares CAMP4 Therapeutics and Genelux”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CAMP4 Therapeutics | $3.50 million | 69.03 | -$80.40 million | ($2.32) | -1.66 |
| Genelux | $10,000.00 | 11,174.28 | -$32.15 million | ($0.86) | -2.87 |
Genelux has lower revenue, but higher earnings than CAMP4 Therapeutics. Genelux is trading at a lower price-to-earnings ratio than CAMP4 Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
CAMP4 Therapeutics has a beta of 0.27, meaning that its share price is 73% less volatile than the S&P 500. Comparatively, Genelux has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent recommendations for CAMP4 Therapeutics and Genelux, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CAMP4 Therapeutics | 1 | 1 | 6 | 0 | 2.62 |
| Genelux | 1 | 0 | 3 | 1 | 2.80 |
CAMP4 Therapeutics currently has a consensus price target of $9.71, indicating a potential upside of 152.32%. Genelux has a consensus price target of $18.00, indicating a potential upside of 628.74%. Given Genelux’s stronger consensus rating and higher possible upside, analysts clearly believe Genelux is more favorable than CAMP4 Therapeutics.
Profitability
This table compares CAMP4 Therapeutics and Genelux’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CAMP4 Therapeutics | -2,543.74% | -252.79% | -85.65% |
| Genelux | N/A | -205.85% | -138.79% |
Summary
Genelux beats CAMP4 Therapeutics on 10 of the 15 factors compared between the two stocks.
About CAMP4 Therapeutics
CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location. The company also offers telematics products, including asset tracking units, mobile telematics devices, fixed and mobile wireless gateways, and routers; and advanced telematics products for the broader connected vehicle and Internet of Things marketplace, which enable customers to optimize their operations by collecting, monitoring, and reporting business-critical information and desired intelligence from remote and mobile assets. In addition, it offers professional services, including project management, engineering services, and installation services. The company sells its products and services to customers in the automotive, telecommunications, industrial equipment, transportation and logistics, government and municipalities, insurance, original equipment manufacturers, and leasing companies. It markets through direct sales organization, channel partner program, original equipment manufacturers, and independent sales representatives and distributors, as well as its websites and digital platform. The company was incorporated in 1981 and is headquartered in Irvine, California.
About Genelux
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Receive News & Ratings for CAMP4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CAMP4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
